Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

11.05.2023 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the European Hematology Association (EHA) Congress, and the International Conference on Malignant ...

Related Keywords

United States ,Japan ,South Korea ,Taiwan ,Amit Verma ,Saloman Manier ,Alit Taher ,Andrew Wei ,Hemophagocytic Lymphohistiocytosis ,Bartl Scott ,Jonathan Spicer ,Paul David Harker Murray ,Haifa Kathrin Al Ali ,Javier Munoz ,Javidj Moslehi ,Krina Patel ,Farrukh Awan ,Rafat Abonour ,Kevin Joseph Harrington ,Melissa Alsina ,Lorettaj Nastoupil ,Marcs Raab ,Jean Marie Michot ,Franck Morschhauser ,Josephj Sacco ,Mitsuho Imai ,Dirk Schadendorf ,David Paul Carbone ,Yelenay Janjigian ,Hartmut Goldschmidt ,Julia Piasecki ,Guillermo Garcia Manero ,David Cella ,Aaron Thomas Gerds ,Sandyw Wong ,Jessica Jiyeong Lin ,Cassandra Vandenberg ,Heinz Josef Lenz ,Bristol Myers Squibb ,Francesco Passamonti ,Adeolay Makinde ,Thomasd Coates ,Michel Delforge ,Susan Bal ,Mahrukhm Syeda ,Bruno Paiva ,Rashaun Fleming ,Keri Maher ,Faisal Faak ,Elena Elimova ,Vikas Gupta ,Robertj Motzer ,Monal Martin ,Kazuto Nakamura ,Paulg Richardson ,Koichi Azuma ,Nizarj Bahlis ,Husseina Tawbi ,Shailender Bhatia ,Sudipto Mukherjee ,Yi Lin ,Tanya Siddiqi ,John Kelly ,Gail Roboz ,Uwe Platzbecker ,Amerm Zeidan ,John Mascarenhas ,Linkedin ,Youtube ,Twitter ,Facebook ,Instagram ,Laboratory Abnormalities ,Exchange Commission ,Ono Pharmaceutical Co ,Important Safety Information ,Prescribing Information ,Boxed Warnings ,Myers Squibb ,Investor Event ,Connect Myeloid Registry ,Myelodysplastic Syndromes ,Neck Cancer ,Chronic Lymphocytic Leukemia ,Plasma Cell Dyscrasia ,Non Small Cell ,Non Small Cell Metastatic ,Cellular Therapies ,Richter Syndrome ,Double Hit Lymphomas ,Better Future ,Release Syndrome ,Risk Evaluation ,Mitigation Strategy ,Neurologic Toxicities ,Fatal Immune Mediated Adverse ,Full Prescribing Information ,Allogeneic Hematopoietic Stem Cell ,Multiple Myeloma ,Lipase Elevation ,Adverse Cardiac Events ,Product Characteristics ,Macrophage Activation Syndrome ,Igg Secondary Malignancies ,Operate Machinery ,Mediated Nephritis ,Drug Rash ,Nervous System ,Connective Tissue ,Adverse Reactions ,Ono Pharmaceutical ,Profit Share Agreement ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,